Method for early diagnosis of motor-induced muscle micro-injury by using urine metabolite-type biomarker
By detecting specific metabolites in urine, the problem of early diagnosis of motor muscle microinjury in the prior art has been solved, and non-invasive and accurate urine detection is achieved, which is suitable for the popularization of national fitness.
Patent Information
- Application Number
- CN202411154316.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-21
- Publication Date
- 2024-11-26
AI Technical Summary
The existing technology is difficult to diagnose sports muscle microinjury (EIMD) in the early stage, and the measurement of blood biochemical indexes is invasive and not suitable for the popularization of national fitness. The existing non-invasive methods rely on expensive professional instruments and are not accurate enough to diagnose.
By detecting specific metabolite-type biomarkers in urine, including oleoylphosphocholine, oleic amide, L-tryptophan, 1-stearoyl-SN-glycerol-3-phosphoylcholine and lysophosphatidylyl The standardized concentration of choline was 18:0, and urine samples were analyzed using targeted metabolomics technology to screen out biomarkers that could early diagnosis of EIMD.
It has achieved early and non-invasive diagnosis of motor muscle microinjury in urine, with high sensitivity and specificity, avoiding the invasive risk of blood measurement, and is suitable for national fitness applications.
Smart Images

Figure CN119023977A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of sports injury detection, and specifically relates to a method for early diagnosis of sports muscle micro-injury using urine metabolite biomarkers Background Art
[0002] Fitness is an effective means to promote health, prevent chronic diseases, and assist in post-illness recovery. At present, China is widely carrying out national fitness activities, promoting the integration of national fitness into daily life, and requiring young students to participate in moderate-intensity sports activities more than 3 times a week. However, due to the lack of scientific fitness knowledge and fitness methods, fitness may also pose sports risks. In the early stages of periodic physical exercise or when engaging in physical exercise that exceeds daily intensity, the most common sports risk is exercise-induced muscle damage (EIMD). The main cause of EIMD is high-intensity eccentric contraction of skeletal muscle, but the physiological mechanism is still being analyzed. It is generally believed that eccentric contraction first exerts mechanical pressure on skeletal muscle, over-stretches the sarcomere and myocyte skeleton, and destroys the integrity of the muscle cells. Then, the intracellular Ca 2+ Overload and oxidative stress free radicals create metabolic stress, leading to accelerated protein hydrolysis and cell membrane damage. Finally, muscle cell fragments activate the immune response of the microenvironment, which may lead to more severe muscle cell damage. Although the physiological mechanism is not yet fully clear, the phenotype and consequences of EIMD have been well reported. The most typical phenotype of EIMD is delayed onset muscle soreness (DOMS), which occurs 24 hours after exercise, which interferes with daily activities, and severe EIMD may also cause rhabdomyolysis, leading to kidney disease and even black urine. Therefore, early diagnosis of EIMD is very important for scientific fitness and avoiding exercise risks.
[0003] DOMS is the most typical symptom of EIMD, but DOMS occurs late and obviously cannot be used for early diagnosis of EIMD. EIMD is usually accompanied by local edema and local inflammation, and these phenotypes are also delayed. At present, certain biochemical indicators in the blood are considered to be able to diagnose EIMD early. When muscle cells are damaged, intracellular creatine kinase (CK) and lactate dehydrogenase (LDH) will be released, so the increase of CK and LDH in the blood is considered to be able to indicate the occurrence of EIMD. At the same time, EIMD is accompanied by increased oxidative stress in the body, leading to changes in total intracellular antioxidant capacity, superoxide dismutase, and peroxide reductase, but there is a lack of unified diagnostic criteria. In addition, the occurrence of EIMD is accompanied by local immune reactions, so the increase of immune factors (such as interleukin-6) in the blood also suggests EIMD, but this indicator lacks specificity. At the same time, EIMD is common in overtraining, and indicators such as α-hydroxybutyrate dehydrogenase (HBDH) will also increase after overtraining, which can assist in the diagnosis of EIMD. However, all of the above biochemical indicators are invasive measurements. Invasive measurements require professional medical staff and are difficult to promote in national fitness. They are only suitable for professional athletes. More importantly, invasive measurements bring the risk of functional interference and secondary infection, and even professional athletes cannot measure frequently. Therefore, it is of great significance to explore non-invasive methods for early diagnosis of EIMD.
[0004] At present, some studies have reported methods for non-invasive diagnosis of EIMD. Since EIMD will cause a significant decrease in muscle strength, Hunter et al. reported the use of tension myography to diagnose EIMD, but the decrease in muscle strength can only be observed 24 hours after exercise. Fulford et al. reported the use of magnetic resonance technology to non-invasively observe muscle morphology, but changes in muscle micromorphology also occurred 24 hours after exercise. Compared with the above two methods, electromyographic signals are believed to be able to instantly reflect the state of muscle excitation and the rate of neuromuscular signal conduction, but the correlation with EIMD is still unclear. At the same time, all of the above methods rely on expensive professional instruments and are difficult to apply to national fitness. On the other hand, the metabolic stress that induces EIMD will cause changes in the body's metabolism. Therefore, in addition to specific biochemical indicators in the blood, metabolites in the urine may also change significantly. Among these metabolites, some metabolites may be able to sensitively and specifically reflect EIMD and become potential biomarkers. Therefore. By utilizing the urine biomarkers of EIMD and establishing a point-of-care detection method for urine biomarkers, it is expected that EIMD can be diagnosed early and non-invasively using urine.
[0005] The basis for early diagnosis of EIMD using urine is to screen for urine biomarkers of EIMD. At present, a series of reports have been published on changes in urine metabolites before and after fitness. For example, Sun et al. compared the changes in urine metabolites of 19 athletes after an 800-meter sprint and found that 11 metabolites were significantly upregulated and 5 metabolites were significantly downregulated. In addition, other studies have analyzed changes in urine metabolites after common exercises, including football games, cycling, sub-maximal endurance cycling, marathons, and strength training. Compared with athletes, untrained people are less adaptable to the physiological stress generated by training and therefore show different changes in urine metabolites. All these studies have shown that exercise can significantly cause changes in urine metabolites, and that the changes in urine metabolites are different between athletes and untrained people. Moreover, changes in urine metabolites are also related to training intensity and training mode. However, these studies basically did not analyze the EIMD symptoms of the subjects, so it was impossible to explore biomarkers in urine that reflect EIMD. At present, only one study has analyzed changes in urine metabolites after the subjects developed EIMD. In this study, it was found that alanine, ethanol, lactate, and asparagine in the urine of the subjects increased significantly after EIMD, suggesting that they may be used as urinary biomarkers for EIMD. However, all of these metabolites did not change significantly immediately after exercise and could not be used for early diagnosis of EIMD. Summary of the invention
[0006] The present invention reports a method for early diagnosis of sports-induced muscle micro-injury using urine metabolite biomarkers, the specific contents of which are:
[0007] 1. A method for early diagnosis of exercise-induced muscle microdamage (EIMD) using urine metabolite biomarkers, characterized in that early diagnosis of EIMD can be achieved by detecting the standardized concentration of urine metabolite biomarkers of subjects and comparing the detection results with the normal standardized concentrations of the biomarkers; the urine metabolite biomarkers include oleoylphosphocholine (1-Oleoyl-Sn-Glycero-3-Phosphocholine), oleamide (Oleamide), L-tryptophanol (Tryptophanol), 1-stearoyl-SN-glycerol-3-phosphatidylcholine (1-Stearoyl-Sn-Glycerol-3-Phosphocholine), and lysophosphatidylcholine 18:0 (LysoPC 18:0).
[0008] 2. According to the above method, it is characterized in that early diagnosis of EIMD can be achieved by detecting at least one urine metabolite-type biomarker.
[0009] 3. According to the above method, it is characterized in that the urine metabolite biomarker comes from urine.
[0010] 4. According to the above method, the standardized concentration of the urine metabolite-type biomarker is calculated by the ratio of the biomarker concentration to the creatinine concentration in the same sample.
[0011] 5. According to the above method, the implementation steps include:
[0012] (1) Collect midstream urine samples from subjects;
[0013] (2) detecting the standardized concentration of one or more urine metabolite biomarkers in the sample, including 1-Oleoyl-Sn-Glycero-3-Phosphocholine, Oleamide, L-Tryptophanol, 1-Stearoyl-Sn-Glycerol-3-Phosphocholine, and LysoPC 18:0;
[0014] (3) Comparing the detected standardized concentration of the urine metabolite-type biomarker with the normal standardized concentration of the biomarker.
[0015] Compared with previous literature reports, this patent discloses for the first time a urine metabolite-type biomarker for early diagnosis of EIMD, and also reports a method for early diagnosis of EIMD using urine metabolite-type biomarkers. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] Figure 1 Changes of serum biochemical indexes in EIMD patients (a: CK; b: LDH; c: HBDH)
[0017] Figure 2 Overall changes in urine metabolites (a: PCA analysis; b: heat map and cluster analysis)
[0018] Figure 3 Analysis of urine differential metabolites (a: volcano plot analysis; b: matchstick plot analysis)
[0019] Figure 4 Diagnostic performance of urine metabolite-based biomarkers and serum biochemical indices (a: oleoylphosphocholine; b: oleamide; c: L-tryptophanol; d: 1-stearoyl-SN-glycero-3-phosphocholine; e: lysophosphatidylcholine 18:0; f: CK) DETAILED DESCRIPTION
[0020] Eighteen untrained / non-exercise male youths were recruited as subjects (ethical review number: V20211108) and rowing machine training with a resistance value of 30 and a duration of 30 min was carried out. Figure 1 The changes of biochemical indicators related to EIMD in the blood of 18 subjects before and after training were shown. The CK level of the 18 subjects before exercise was 91.39±17.25U / L, while the level of CK immediately after exercise increased significantly to 116.94±20.59U / L (p<0.05). Previous studies have also found similar phenomena. When the subjects underwent EIMD modeling, the CK in the blood increased significantly immediately after training. Considering that the increase in CK comes from the destruction of muscle cell integrity and the outflow of endosomal solution, the increase in CK immediately after training in the subjects in this study indicates that the subjects have EIMD. The occurrence of EIMD after the subjects experienced rowing machine training is mainly due to two reasons. First, none of the 18 subjects had ever carried out rowing machine training, and rowing machine training was an unfamiliar exercise for each subject. Second, none of the 18 subjects had exercise habits, and rowing machine training with a resistance value of 30 and a duration of 30min was basically very challenging for each subject. Moreover, rowing machine training is a resistance training that requires the mobilization of more than 80% of the body's muscles, and each stretch and release includes eccentric and concentric contractions. Therefore, after the subjects experienced unfamiliar high-intensity rowing machine training, their muscles were damaged, resulting in a significant increase in CK. LDH in the blood is also considered to indicate EIMD. As expected, the LDH level in the subjects' blood also increased significantly (p < 0.05), which is similar to what was reported in previous studies. Therefore, the significant increase in CK and LDH in the subjects' blood after completing the training jointly confirmed that the training induced EIMD in the subjects.
[0021] On the other hand, the biochemical indicators that assist in the diagnosis of EIMD and the subjects' physical performance also changed, proving the above conclusions. First, HBDH reflects overtraining, and EIMD often occurs in overtraining. In this study, the HBDH level in the subjects' blood increased from 122.56±14.96U / L to 134.22±17.39U / L, and the increase in HBDH was significant. Then, 1-2 days after rowing machine training, all subjects reported muscle soreness, that is, obvious DOMS. Interestingly, the areas of muscle soreness reported by different subjects may be different, which may be because rowing machine training mobilizes almost all the muscles in the body, and the muscles of different subjects have individual differences in sensitivity to EIMD.
[0022] Using targeted metabolomics technology, the differences in metabolites in the subjects' urine at rest and after training were analyzed. Urine sampling was performed at the same time and under the same dietary conditions to avoid the influence of circadian rhythm and dietary metabolism. Targeted metabolomics technology discovered and identified 742 metabolites in 36 samples. Three-dimensional principal component analysis (PCA) was used to compare the differences in urine metabolites before and after training. As shown in the figure, the three principal components together explained more than 80% of the differences in urine metabolites. Basically, the urine samples before training were clustered in one area, while the urine samples after training were clustered in another area, indicating that training induced significant changes in urine metabolites, which is similar to the results of previous studies. For the cluster analysis of 36 urine samples, it can be seen that the samples of 18 subjects before training were clustered into 1 group, while the samples after training were clustered into 1 group. This result shows that the effect of training on urine metabolites exceeds the individual differences between subjects, and also shows that the changes in metabolites after training have similar trends.
[0023] Paired t-test was used to screen metabolites with significant changes in urine, of which 53 metabolites showed significant upregulation after training, while 62 metabolites showed significant downregulation after training. At present, a series of literatures have reported changes in urine metabolites after training. Referring to these literatures, it can be summarized that about 30 metabolites have been reported to have significant changes after training, including N-lactoyl-phenylalanine, fumaric acid, hypoxanthine and uridine. The most common of these metabolites are hypoxanthine and uridine. In this study, hypoxanthine increased significantly by 129.81% after training. Similarly, hypoxanthine increased significantly by 170% and 56.89% after cycling and marathon exercise. Similar phenomena were also found for uridine after exercise. It is worth noting that about 80 metabolites have not been reported before, that is, newly discovered metabolites that change after training. Among the metabolites with significant changes, 38 metabolites were upregulated by more than 1.5. These metabolites with larger changes have better biomarker prospects.
[0024] To further analyze the urine biomarkers of EIMD, we compared the ROC curves of all metabolites. According to the AUC area ranking, the top five EIMD urine metabolite biomarkers include 1-Oleoyl-Sn-Glycero-3-Phosphocholine, Oleamide, L-Tryptophanol, 1-Stearoyl-SN-Glycerol-3-Phosphocholine, and LysoPC 18:0. It is worth noting that these urine metabolite biomarkers have high sensitivity and specificity for diagnosing EIMD, and have not been reported yet, so they can be considered as new biomarkers for EIMD. For example, the sensitivity of 1-Oleoyl-Sn-Glycero-3-Phosphocholine reached 90%, and the specificity also reached 90%. In fact, this diagnostic performance has exceeded that of CK and LDH in the blood, whose sensitivity / specificity for diagnosing EIMD is only 77.78% / 83.33% and 66.67% / 72.22%, respectively. Under the best diagnostic performance conditions, the diagnostic thresholds of the five EIMD biomarkers were 0.0097, 0.85, 0.12, 0.018, and 0.024, respectively. All thresholds are not the concentration of the biomarker, but the ratio of the biomarker to creatinine, that is, the standardized concentration, which can avoid the influence of urine hydration status on diagnosis.
Claims
1. A method for early diagnosis of exercise-induced muscle microdamage (EIMD) using urine metabolite biomarkers, characterized in that: Early diagnosis of EIMD can be achieved by detecting the standardized concentration of urine metabolite biomarkers in subjects and comparing the test results with the normal standardized concentrations of the biomarkers; the urine metabolite biomarkers include oleoylphosphocholine (1-Oleoyl-Sn-Glycero-3-Phosphocholine), oleamide (Oleamide), L-tryptophanol (Tryptophanol), 1-stearoyl-SN-glycerol-3-phosphatidylcholine (1-Stearoyl-Sn-Glycerol-3-Phosphocholine) and lysophosphatidylcholine 18:0 (LysoPC 18:0).
2. The method according to claim 1, characterized in that Early diagnosis of EIMD can be achieved by detecting at least one urine metabolite-type biomarker.
3. The method according to claim 1, characterized in that: The urine metabolite-type biomarkers are derived from urine.
4. The method according to claim 1, wherein the standardized concentration of the urine metabolite-type biomarker is calculated by the ratio of the biomarker concentration to the creatinine concentration in the same sample.
5. The method according to claim 1, wherein the implementation steps include: (1) Collect midstream urine samples from subjects; (2) detecting the standardized concentration of one or more urine metabolite biomarkers in the sample, including 1-Oleoyl-Sn-Glycero-3-Phosphocholine, Oleamide, L-tryptophanol, 1-Stearoyl-Sn-Glycerol-3-Phosphocholine, and LysoPC 18:0; (3) Comparing the detected standardized concentration of the urine metabolite-type biomarker with the normal standardized concentration of the biomarker.
